Literature DB >> 12052976

Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study.

Søren Bak1, Ioannis Tsiropoulos, Jens Ole Kjaersgaard, Morten Andersen, Erling Mellerup, Jesper Hallas, Luis Alberto García Rodríguez, Kaare Christensen, David Gaist.   

Abstract

BACKGROUND AND
PURPOSE: Selective serotonin reuptake inhibitors (SSRIs) have been associated with increased risk of bleeding complications, possibly as a result of inhibition of platelet aggregation. Little is known about the risk of intracerebral hemorrhage in users of SSRIs and whether the effect on platelet aggregation reduces the risk of ischemic stroke. We used population-based data to estimate the risk of hemorrhagic and ischemic stroke in users of SSRIs.
METHODS: We performed a nested case-control study in Funen County (465 000 inhabitants), Denmark. All patients with a first-ever stroke discharge diagnosis in the period of 1994 to 1999 were identified, and a validated diagnosis of stroke was reached in 4765 cases. In all, 40 000 controls were randomly selected from the background population. Information on drug use for cases and controls was retrieved from a prescription registry with full coverage of the county. Odds ratios were adjusted for age, sex, calendar year, and use of other medication. To evaluate the effect of various potential confounders not recorded in the register data, we performed separate analyses on data from 2 large population-based surveys with more detailed information on risk factors.
RESULTS: Of 659 patients with hemorrhagic stroke, 21 were current users of SSRIs. The adjusted odds ratio of hemorrhagic stroke in current SSRI users compared with never users was 1.0 [95% confidence interval (CI), 0.6 to 1.6]. Of 2717 patients with ischemic stroke, 100 were current users of SSRIs, and the adjusted odds ratio of ischemic stroke in cases compared with controls was 1.1 (95% CI, 0.9 to 1.4). The survey data indicated that additional confounder control would not have led to an increase in the relative risk estimates.
CONCLUSIONS: Current exposure to SSRIs is not associated with increased risk of intracerebral hemorrhage and is probably not associated with a decreased risk of ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052976     DOI: 10.1161/01.str.0000018589.56991.ba

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  30 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  Depression and incident stroke in women.

Authors:  An Pan; Olivia I Okereke; Qi Sun; Giancarlo Logroscino; JoAnn E Manson; Walter C Willett; Alberto Ascherio; Frank B Hu; Kathryn M Rexrode
Journal:  Stroke       Date:  2011-08-11       Impact factor: 7.914

Review 3.  Medically serious adverse effects of newer antidepressants.

Authors:  Rajnish Mago; Rajeev Mahajan; Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

4.  Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study.

Authors:  Antonios Douros; Sophie Dell'Aniello; Golsa Dehghan; Jean-François Boivin; Christel Renoux
Journal:  Neurology       Date:  2019-08-07       Impact factor: 9.910

5.  Measuring psychotropic drug exposures in register-based studies--validity of a dosage assumption of one unit per day in older Finns.

Authors:  Maria Rikala; Sirpa Hartikainen; Leena K Saastamoinen; Maarit Jaana Korhonen
Journal:  Int J Methods Psychiatr Res       Date:  2013-05-16       Impact factor: 4.035

6.  Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies.

Authors:  A Biffi; L Scotti; G Corrao
Journal:  Eur J Clin Pharmacol       Date:  2017-01-09       Impact factor: 2.953

Review 7.  Pharmacological management of depression in patients with cancer: practical considerations.

Authors:  Riccardo G V Torta; Valentina Ieraci
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 8.  Strategies for dementia prevention: latest evidence and implications.

Authors:  Gopalkumar Rakesh; Steven T Szabo; George S Alexopoulos; Anthony S Zannas
Journal:  Ther Adv Chronic Dis       Date:  2017-06-27       Impact factor: 5.091

Review 9.  [SSRI - treatment and bleeding. What risks do we take?].

Authors:  T Strubel; A Birkhofer; G Mössmer; H Förstl
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

10.  Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study.

Authors:  Xavier Vidal; Luisa Ibáñez; Lourdes Vendrell; Ana Conforti; Joan-Ramon Laporte
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.